公开(公告)号：US20240092773A1

公开(公告)日：2024-03-21

申请号：US17786387

申请日：2020-12-22

Applicant: UCB Biopharma SRL

Inventor： Timothy John NORMAN ,  Zhaoning ZHU ,  Selvaratnam SUGANTHAN ,  Konstantinos RAMPALAKO ,  James MADDEN ,  Jag Paul HEER ,  Richard Jeremy FRANKLIN ,  Rickki Lee CONNELLY ,  Thierry DEMAUDE ,  Gregory William HASLETT ,  Benedicte LALLEMAND ,  Nathaniel Julius Thomas MONCK ,  Julian Hugh ROWLEY ,  Giancarlo TRANI

IPC: C07D471/04 ,  C07D401/14 ,  C07D217/02 ,  C07D401/12 ,  C07D237/30 ,  C07D403/12 ,  C07D403/14 ,  C07D491/04 ,  C07D401/04 ,  C07D413/14 ,  C07D417/12

CPC classification number: C07D471/04 ,  C07D401/14 ,  C07D217/02 ,  C07D401/12 ,  C07D237/30 ,  C07D403/12 ,  C07D403/14 ,  C07D491/04 ,  C07D401/04 ,  C07D413/14 ,  C07D417/12

Abstract: The present invention relates to dihydro-cyclopenta-isoquinoline derivatives of formula (I): processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular, disorders caused by the interaction of IgE with the FcεRI receptor.

公开(公告)号：US20230303517A1

公开(公告)日：2023-09-28

申请号：US17786394

申请日：2020-12-22

Applicant: UCB Biopharma SRL

Inventor： Timothy John NORMAN ,  Douglas BYRNE ,  Julian Hugh ROWLEY ,  Giancarlo TRANI ,  Konstantinos RAMPALAKOS ,  Nathaniel Julius Thomas MONCK ,  Benedicte LALLEMAND ,  Gregory William HASLETT ,  Rickki Lee CONNELLY ,  Jag Paul HEER ,  James MADDEN ,  Oliver PHILPS ,  Selvaratnam SUGANTHAN ,  Zeshan YOUSUF ,  Richard John MEARS

IPC: C07D401/14 ,  C07D221/06 ,  C07D401/12 ,  C07D405/14 ,  C07D413/14 ,  C07D409/12 ,  C07D498/10 ,  C07D471/04 ,  C07D417/12 ,  C07D413/12 ,  C07D487/04 ,  C07D405/12

CPC classification number: C07D401/14 ,  C07D221/06 ,  C07D401/12 ,  C07D405/14 ,  C07D413/14 ,  C07D409/12 ,  C07D498/10 ,  C07D471/04 ,  C07D417/12 ,  C07D413/12 ,  C07D487/04 ,  C07D405/12

Abstract: The present invention relates to dihydrocyclopenta-isoquinoline-sulfonamide derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FcεRI receptor.

公开(公告)号：US20240294534A1

公开(公告)日：2024-09-05

申请号：US18572274

申请日：2022-06-30

Applicant: UCB BIOPHARMA SRL

Inventor： Gareth Neil BRACE ,  Daniel Christopher BROOKINGS ,  Shuyu CHU ,  Rickki Lee CONNELLY ,  Anne Marie FOLEY ,  James Richard FROST ,  Ellen Olivia GALLIMORE ,  Paul GOLDSMITH ,  James Andrew JOHNSON ,  James Thomas REUBERSON ,  Robert STRAKER ,  Richard David TAYLOR ,  Luigi Piero STASI

IPC: C07D487/04 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/541

CPC classification number: C07D487/04 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/541

Abstract: A series of substituted imidazo[1,2-b][1,2,4]triazine derivatives of formula (I), being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.